Table 3.
Determination of SUVmax cut-offs for pathological T-stage
| T-stage | SUVmax cut-off | AUROC curve | 95% confidence interval |
|---|---|---|---|
| CRT [−] group | |||
| T ≥ T1 | 1.9 | 1.00a | 0.92 ~ 1.00 |
| T ≥ T2 | 4.4 | 0.88a | 0.75 ~ 0.96 |
| T ≥ T3 | 6.5 | 0.95a | 0.84 ~ 0.99 |
| T : T4 | 13.0 | N/Ab | N/A |
| CRT [+] group | |||
| T ≥ T1 | 3.4 | 0.89a | 0.77 ~ 0.95 |
| T ≥ T2 | 3.9 | 0.93a | 0.83 ~ 0.98 |
| T ≥ T3 | 5.5 | 0.95a | 0.85 ~ 0.99 |
| T : T4 | 6.2 | 0.95a | 0.86 ~ 0.99 |
a p < 0.05
bData unavailable because there was only one patient with a T4 tumor in the CRT[−] group
AUROC area under the receiver-operating-characteristic, CRT chemoradiotherapy, SUV max maximal standardized uptake value